Kimberly Blackwell
Chief Executive Officer at Zentalis Pharmaceuticals Inc.
Sits on 3 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 10 years
- Director since
- 2023
10 years of board service in total across 3 boards, counting each seat separately. Longest: Zentalis Pharmaceuticals Inc., 3 years.
Zentalis Pharmaceuticals Inc.
Director · Chief Executive Officer
Monte Rosa Therapeutics Inc.
Director
Century Therapeutics Inc.
Director
Chief executive roles
Zentalis Pharmaceuticals Inc.
· Chief Executive Officer
Until November 2024
· Former
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 1, 2024 | Zentalis Pharmaceuticals Inc. | Grant or award | +250,000 | — | — |
| Feb 1, 2024 | Zentalis Pharmaceuticals Inc. | Shares withheld for tax | −20,655 | $11.69 | $241,457 |
| Nov 13, 2023 | Zentalis Pharmaceuticals Inc. | Open-market purchase | +5,000 | $10.29 | $51,450 |
| Feb 1, 2023 | Zentalis Pharmaceuticals Inc. | Grant or award | +244,800 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.